Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Liabilities: 2023-2025

  • Zhengye Biotechnology Holding's Total Liabilities was N/A to $19.3 million in Q2 2025 from the same period last year, while for Dec 2024 it was $19.3 million, marking a year-over-year decrease of 13.59%. This contributed to the annual value of $19.3 million for FY2024, which is 15.19% down from last year.
  • According to the latest figures from Q2 2025, Zhengye Biotechnology Holding's Total Liabilities is $19.3 million, which was up 0.08% from $19.3 million recorded in Q4 2024.
  • In the past 5 years, Zhengye Biotechnology Holding's Total Liabilities registered a high of $22.3 million during Q4 2023, and its lowest value of $19.3 million during Q4 2024.
  • For the 3-year period, Zhengye Biotechnology Holding's Total Liabilities averaged around $20.3 million, with its median value being $19.3 million (2025).
  • Data for Zhengye Biotechnology Holding's Total Liabilities shows a maximum YoY decreased of 13.59% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Total Liabilities (Quarterly) stood at $22.3 million in 2023, then dropped by 13.59% to $19.3 million in 2024, then reached $19.3 million in 2025.
  • Its Total Liabilities stands at $19.3 million for Q2 2025, versus $19.3 million for Q4 2024 and $22.3 million for Q4 2023.